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A B S T R A C T
Bacterial cellulose (BC) is a biopolymer synthesized by certain acetic acid bacteria strains. The safety of BC
regarding its potential use in food applications is here reviewed. The acute, sub-acute and subchronic oral
toxicity assays showed that consumption of BC had no adverse eﬀects in rats. Several studies demonstrated that
BC is not genotoxic, did not induce chromosomal aberrations in CHO cells under both non-activating and me-
tabolic activating conditions, is inactive in the in vitro Rat Primary Hepatocyte Unscheduled DNA Synthesis
Assay, had no reproductive toxicity in mice and exerted no embryotoxicity and teratogenicity eﬀects in rats.
Several studies on the BC in biomedical applications further reinforces its safety: a primary eye and dermal
irritation studies in the rabbit showed that BC was non-irritating. The inﬂammatory reaction to subcutaneously
implanted BC has been evaluated in animal models and for diﬀerent periods of time, demonstrating that BC is
biocompatible and does not trigger a harsh inﬂammatory reaction.
Altogether, and considering its longstanding history of human consumption in Asian countries, as well as its
utilization in biomedical devices, it may be concluded that BC is safe for applications in food technology.
1. Introduction
The determination of toxicants in foods/food substances has become
increasingly important, to ensure that the beneﬁts of the substances
intended for use by humans, outweigh the risks from their use. Many
countries have a well-established regulatory framework (and under
constant revisions), to ensure the proper scientiﬁc evaluation of foods,
food additives and ingredients, processing aids and food contacting
substances, before their market approval. The toxicity tests that food
operators are required to provide, for a pre-market approval of their
products, depends on the type of substance, its intended use and on the
regulations of a particular country. To this eﬀect, several standard tests
are available to evaluate diﬀerent eﬀects such as acute, sub-acute, sub-
chronic and chronic toxicity, carcinogenicity, mutagenicity, re-
productive and developmental toxicity, neurotoxicity, and several in
vitro tests. Some products may require additional toxicity test such as
irritancy and skin sensitization studies [1–7].
The safety of numerous kinds of plant cellulose and their derivative
products has been extensively reviewed by national and international
regulatory agencies such as the US Food and Drug Administration
(FDA), The European Food Safety Authority (EFSA), the Joint FAO/
WHO Expert Committee on Food Additives (JEFCA), the Select
Committee on Generally Recognized as Safe (GRAS) Substances
(SCOGS). The information provided below includes a comprehensive
review on the toxicological data available for bacterial cellulose.
Bacterial cellulose (BC) is a pure cellulose exopolysaccharide pro-
duced by certain strains of acetic acid bacteria, such as those of the
Komagataeibacter genus. The cellulose synthesized by these strains is
identical to that of plants, regarding its molecular formula and poly-
meric structure. However, BC presents in general, a higher crystallinity.
Also, BC is chemically pure, i.e. it is free of lignin, hemicelluloses and
other biogenic compounds. Under static culture conditions, the syn-
thetized BC, is presented as a gelatinous ﬁlm consisting of a 3D nano-
ﬁbrilar arrangement of pure cellulosic ﬁbres (Fig. 1). These randomly
assembled ribbon-shaped ﬁbrils are less than 100 nm wide and com-
posed of elementary nanoﬁbrils, aggregated in bundles with lateral size
of 7–8 nm; these ﬁbrils have several micrometres in length [8–12]. The
taxonomy of these bacteria [13], the BC biosynthesis [14] and potential
applications in food [15–17], have been extensively reviewed.
2. Dietetic properties and human consumption
In Asian countries, BC is already produced at large scale and has a
long history of use, being marketed under the trade name “nata de
coco” [18–20]. Ever since its discovery in the eighteenth century, nata
de coco gained widespread popularity in Asian countries, being ﬁrst
produced in large scale in the Philippines [21]. Philippines and In-
donesia are the major producers and exporters of nata de coco products
for human consumption. Thailand, Vietnam and Malaysia are also
among the most representatives commercial producers (Phisalaphong
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and Chiaoprakobkij 2013). Among non-traditional coconut export
products in 2009, nata de coco was the second largest, earning US
$6034 million from the sale of 6051 MT. The greatest market for nata
de coco was Japan (77.8%) and the second largest market was the USA.
From 2009–2011, the volume of nata exports from the Philippines has
been within a calculated and steady average range of 6000 MT which
corresponded to a market value of US$6 million [22,23]. These ﬁgures
demonstrate the long-standing human consumption of nata de coco/
bacterial cellulose. There are, to our knowledge, no reported cases of
health related issues associated to the human consumption of BC or
nata de coco, thus unequivocally supporting the claim on its safety. In
fact, several studies demonstrate beneﬁcial eﬀects from the dietetic
point of view, as observed bellow.
A study by Chau et al. [24] investigated and compared the hypoli-
pidemic and hypocholesterolemic eﬀects of plant cellulose and BC,
speciﬁcally, the absorption and excretion of lipids and cholesterol in
Golden Syrian hamsters’ diets (Table 1). Three types of diets were
prepared, the diﬀerence between them being the addition of bacterial
cellulose on the “bacterial cellulose diet”, plant cellulose on the “cel-
lulose diet”, and the “ﬁbre-free diet” (a control diet, without ﬁbre). All
diets were supplemented with cholesterol (2.0 g/kg of diet) to induce
the alimentary hypercholesterolemia in hamsters; also the insoluble
ﬁbre content was standardized to 50 g ﬁbre/kg of diet in the diets
containing ﬁbre. For 30 days, food and drinking water were supplied ad
libitum.
The results showed that the serum triglyceride concentrations in
hamsters fed with BC and plant cellulose diets, were signiﬁcantly re-
duced, by 55.5 and 46.6%, respectively, as compared to the ﬁbre-free
diet. No signiﬁcant changes in the serum high-density lipoprotein
(HDL) cholesterol concentration were observed among the three diet
groups. However, signiﬁcantly higher HDL/total cholesterol ratios were
found for the plant cellulose and BC supplemented groups (0.60 and
0.65, respectively) versus the ﬁbre-free group (0.50) suggesting the
higher antiatherogenic potential of BC. Further, the administration of
both types of cellulose to hamsters, eﬀectively decreased the con-
centration of serum total cholesterol (by 17.4% with plant cellulose and
by 27.9% with BC) and also decreased the serum low-density lipopro-
tein (LDL) cholesterol (plant cellulose: −41.9%; BC: −47.9%). The
cation-exchange capacity of bacterial cellulose, 67.5 mequiv/Kg of
ﬁbre, was found to be 6-fold higher than that of plant cellulose. The
higher cation-exchange capacity of BC was proposed to better entrap,
destabilize and disintegrate a lipid emulsion, leading to a decrease in
diﬀusion and absorption of cholesterol and lipids. By the end of the
experiment, no signiﬁcant variations in the mass of the hamsters’
visceral organs including small intestine, cecal wall, colon plus rectum,
liver and kidney, among the three types of diets, were observed.
Chemical analysis of the hamsters’ liver tissues revealed that the ad-
dition of BC to the diet was more eﬀective in reducing the concentration
of the liver total lipids (-10.3%) and liver cholesterol (-16.3%) than
with plant cellulose (-6.5% and −11.8% respectively), as compared to
the ﬁbre-free diet. Analysis of the hamsters’ faeces showed that, as
compared to the “ﬁbre-free diet” group, the group fed with plant cel-
lulose and BC had an increase in the excretion of total lipids (plant
cellulose: +44%; BC: +82%), cholesterol (plant cellulose: +36%; BC:
+103%) and bile acids (plant cellulose: +159%; BC: +379%). Also,
the faecal moisture content of hamsters fed with BC was higher than
those fed the ﬁbre-free and plant cellulose diets (+37% (BC) and
+20% (plant cellulose)). With the addition of plant cellulose and BC to
ﬁbre-free diet, the faecal dry weight increased by +42% and +49%,
respectively. No signiﬁcant diﬀerences in the faecal dry weight were
observed between the plant cellulose and BC groups. The results thus
indicated that BC was able to incur a higher output of total lipids,
cholesterol and bile acids in faeces than plant cellulose.
Okiyama et al. [25] studied the faecal excretion and transit time of
BC in rats for up to 16 days (Table 1). Eight weeks old male Wistar rats
were fed with a diet containing 5% of BC, or plant cellulose powder or
guar gum. Feeding was provided twice a day and drinking water was
supplied ad libitum.
Rats fed with BC-containing meals showed the greatest increase
(+223%) in faecal weight. Addition of BC to the diet decreased the
transit time by 50%, as compared to no ﬁbre diet group. There were no
diﬀerences on lipoprotein cholesterol levels in plasma (total choles-
terol, HDL, and LDL fractions) between the dietary ﬁbres group and
ﬁbre-free diet (control). The guar-meal gum group had signiﬁcantly
lower lipoprotein cholesterol levels, as compared to the dietary ﬁbre
groups. Both BC and guar decreased (-52%) neutral sterol excretion in
faeces and increased (+106%) faecal bile acid excretion. The propor-
tion of coprostanol to total neutral sterols in the cecum was not sig-
niﬁcantly diﬀerent between rats fed with BC and those fed with the
ﬁbre-free diet.
Mesomya et al. [26] compared the serum triglyceride and the serum
cholesterol lowering eﬀect of ﬁve kinds of dietary ﬁbre diet on
weanling male Sprague-Dawley rats (Table 1). These diets had diﬀerent
ﬁbre and nutrient proportions: diet 1 was had a total of 33% (m/m)
dietary ﬁbre from unpolished rice, mung bean, sweet corn and 22% BC;
Diet 2 had 60% ﬁbre from the same plant sources and 40% BC. Diets 3,
4 and 5 had 100% apple pectin, plant cellulose and casein respectively.
Cholesterol content was of 13%, 11.4%, 14.2%, 14.1% and 13.5% mg/
100 g in diets 1, 2, 3, 4 and 5, respectively. After four weeks of study,
diet 2 gave the best lowering eﬀect of serum triglyceride in rats, as
compared with those fed with apple pectin (diet 3) and cellulose (diet
4), even though the total dietary ﬁbre content in diet 2 (2.86%) was
lower than that of apple pectin diet 3 (7.76%) and of plant cellulose diet
4 (10.39%). Diet 2 however, had no eﬀect in lowering serum choles-
terol levels.
Mesomya et al. [27] investigated the eﬀects of the cereal and BC
supplementation on the serum lipids of hyperlipidemic human subjects
for a period of 24 weeks: 4 weeks without (as the control) and 20 weeks
with supplementation (Table 1). The supplements (15 g) were given
twice daily for these 20 weeks, and consisted of 40% (m/m) BC, 6% (m/
m) unpolished rice, 36% (m/m) sweet corn and 18% (m/m) mung bean.
After 20 weeks, the subjects who complied with the dietary assignment
(≥90% of the time; 15 subjects) were classiﬁed as group A, and those
with< 90% (7 subjects), as group B. During the ﬁrst four weeks
(control) the subjects showed no signiﬁcant changes in serum lipid le-
vels. Afterwards, Group A showed gradually decreasing levels of serum
total triglyceride (TC). By week 16/20 under supplementation, the
serum total cholesterol (TC) level decreased by 20%.
A summary of the above-mentioned studies is present in Table 1.
Fig. 1. Scanning electron microscopy of cellulose pellicles and cells from G. xylinum IFO
13693, after 10 days of static culture. Reprinted from Chávez-Pacheco et al., 2005 with
permission from John Wiley & Sons.
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3. Acute and sub-acute oral toxicity
Schmitt et al. [28] tested the acute oral toxicity of a commercial
product named Cellulon® ﬁbre (dried BC:sucrose at a ratio of 1:1) in
both sexes of Sprague-Dawley rats (Table 2). Rats were fed a single oral
dosage of 2000 mg Cellulon/Kg of body weight (bw), via oral intuba-
tion
No deaths occurred during the study that lasted for 15 days. Clinical
signs of gasping respiration and/or hunched posture were observed in
two males through day 2. All males appeared normal from day 4
through day 14. The clinical observations appeared to be mechanical
responses to the dosing regimen, rather than responses to the test ma-
terial. However, a microscopic evaluation of tissues was not conducted.
All female rats were normal throughout the study. No gross pathologic
lesions were observed in any of the animals at necropsy.
Li-ming et al. [29] evaluated the acute oral toxicity of nata de coco
(BC) in both sexes of Kunming mice, according to the Maximum Tol-
erated Dose (MTD) method (Table 2). A total dosage of 15.0 g/kg bw,
equally split in two meals, was administered to the mice by gavage, at 4
and 6 h. In all mice, no abnormal symptoms or death were observed.
Also, anatomical observation of the organs were normal. The maximum
tolerance of 15.0 g/kg bw, was considered to be non-toxic.
Hagiwara et al. [30] evaluated the eﬀect of BC sub-acute adminis-
tration to both sexes of F344 rats for 28 days (Table 2). For this, a
commercial product labelled “fermented cellulose” (composed of 60%
BC, 20% carboxymethyl cellulose (CMC) and 20% sucrose) was in-
corporated at diﬀerent proportions (0, 1.25, 2.5, and 5.0%) into the
rat’s stock powdered diet.
No treatment-related deaths were observed during the 28 days of
the experiment and no treatment-related clinical signs were noted in
any of the treated animals. No signiﬁcant variation from control body
weights was noted in any of the treated groups. There were also no clear
inter-group diﬀerences in food or water consumption. On urinalysis, a
signiﬁcant elevation of sodium was noted in males only of the 5.0%
group; however, the values were within the historical control ranges.
No treatment-related ophthalmological abnormalities were found in
any animals of either control or treated groups. No treatment-related
adverse eﬀects were apparent from the haematology results. On blood
biochemistry, statistically signiﬁcant elevation of alanine amino-
transferase was noted in males of the 2.5 and 5.0% groups. No other
treatment-related changes were apparent from the blood biochemistry
results. No treatment-related macroscopic changes were found in
treated animals at necropsy. Statistically signiﬁcant elevation of re-
lative salivary gland weights was noted in both sexes of the 5.0% group
and of relative kidney weights and relative adrenal weights in 5.0%
females. Despite the statistically signiﬁcant increases in cecum, salivary
gland, kidney, and adrenal weights, observed in both sexes given 5.0%,
these observations were not associated with any histopathological al-
terations. Increased cecum weights in this study was considered a
physiological adaptation related to the ingestion of large amounts of
modiﬁed starch, ﬁbrous ingredients, or other carbohydrates which are
poorly absorbed and have a high osmotic nature. Also, no histopatho-
logical ﬁndings related to test material treatment were observed in the
other organs examined. The No Adverse Observed Eﬀect Level (NOAEL)
was set at the highest dose of 5.0% “fermented cellulose” in the feed,
equivalent to 5331 mg/kg bw/day for males and 5230 mg/kg/day for
females.
Li-ming et al. [29] also evaluated the sub-acute oral toxicity of nata
de coco (BC) in Kunming mice, for 30 days (Table 2). The assay group
was fed with 0 (control) 1.3, 2.5, and 5.0 g/kg bw. The animals in the
dose group were given 1.3, 2.5 and 5.0% cocoa. During the experiment,
no changes in the growth, development body weights was noted in any
of the treated groups; also, no inter-group diﬀerences in food or water
consumption was noted and no treatment-related deaths and clinical
signs were observed. Haematological analysis showed that no inter-
group diﬀerences were noted in haemoglobin, red blood cell count and
leukocytes. The same observations were recorded for blood serum al-
bumin, alanine aminotransferase, alanine aminotransferase, aspartate
aminotransferase, creatinine, cholesterol, triglyceride, blood glucose
and albumin. Histopathological examination of the various groups,
showed no abnormal changes.
A summary of the above-mentioned studies is present in Table 2.
4. Sub-chronic toxicity
Schmitt et al. [28] studied the subchronic toxicity of BC (Cellulon®
ﬁbre) (Table 2). For 13 weeks, test and positive control animals
(Sprague-Dawley rats) received meals containing either BC or micro-
crystalline cellulose (MCC), at levels of 0.5 (low dose group) or 10%
(high dose group) in the diet. Control animals received the same diet
without bacterial cellulose or MCC.
The results from this study revealed that there were no deaths at-
tributable to treatment with Cellulon, MCC or control. Clinical ob-
servations noted during the course of the study (e.g., malocclusion,
lacrimation, alopecia) were not indicative of toxic eﬀects. No statisti-
cally signiﬁcant diﬀerences were observed in mean body weight or
mean body weight gain of male or female rats, when comparisons were
made between test and control groups. Food consumption generally
increased in animals fed with 15% (MCC) and 10% Cellulon), when
compared with the control group. This increase in food consumption
was expected as the animals adjusted for the altered nutritional value of
the diet, as a result of the relatively high test article concentrations in
the feed. However, there were no consistent diﬀerences in food con-
sumption between groups fed with Cellulon and MCC. Cellulon intake
by the 5% and 10% treatment groups was calculated to be of 3200 and
7000 mg/kg/day, respectively, for male rats and 4000 and 8500 mg/
kg/day, respectively, for female rats. MCC intakes were similar to those
of Cellulon. Statistically signiﬁcant diﬀerences in haematology para-
meters included increased mean cell haemoglobin and haematocrit,
platelets and monocytes. Evaluation of serum chemistry parameters
revealed slight but signiﬁcant decreases in total protein, albumin, total
cholesterol, and calcium. None of the aforementioned signiﬁcant dif-
ferences were considered to be toxicologically important, due to a lack
of dose-response relationships, relatively low magnitude of change, lack
of diﬀerences between the control group and Cellulon-treated groups,
and/or lack of important changes in related clinical parameters. There
were no notable gross pathologic ﬁndings at necropsy. Cellulon and
MCC treatment had no eﬀect on organ weights. Microscopic evaluation
of tissues revealed no unusual lesions or patterns of distribution that
might suggest an eﬀect of exposure to Cellulon or MCC. Furthermore,
no histomorphologic alterations of the gastrointestinal tract were evi-
dent.
Li-ming et al. [29] evaluated the subchronic 30-day oral toxicity of
BC on SD male and female rats (Table 2). The sample dosage was de-
signed to be of 1.3, 2.5, 5.0 g BC/kg bw. The control group was fed with
a normal diet. During the experiment, the growth and development of
the animals in each group was normal; there were no death observed in
any group. No clinical symptoms were deemed related to the feeding of
BC. No diﬀerence among groups on organ weight and organ/body
weight ratio were observed. There were no signiﬁcant diﬀerences in the
total weight gain, total food intake and total food consumption between
male and female rats, as compared to the control group. Regarding
haematological indicators, feeding BC had no obvious eﬀect on rats’
haemoglobin, red blood cell count or white blood cell count. Also, rats
fed with BC had similar values of serum albumin, alanine amino-
transferase, alanine aminotransferase, aspartate aminotransferase,
creatinine, cholesterol, triglyceride, blood glucose, albumin as that of
the control group. Regarding the histopathological examination, no
abnormal changes were found between the various groups. In the high
dose group and the control group, vacuolization and hepatic blood
stasis was observed. The liver serosa was intact, and the central vein,
hepatic lobule and portal area were clear. The hepatocellular cord
F. Dourado et al. Toxicology Reports 4 (2017) 543–553
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arranged radially around the central vein. The structure of the renal
capsule was complete, the glomeruli of the cortex, the structure of the
renal capsule was clear; the structure of the gastrointestinal serosa,
muscularis, mucosa, and submucosal layer was also clear; the spleen
capsule was complete. Testicular and ovarian albuginea integrity was
maintained. Visible levels of spermatogenic cells were also recorded.
A summary of the above-mentioned studies is present in Table 2.
5. Genotoxicity & reproductive and developmental toxicology
5.1. Single cell gel electrophoresis assay (comet assay)
Moreira et al. [31] studied the in vitro genotoxicity of BC (Table 3).
For this, the DNA integrity of Chinese hamster ovary (CHO) cells, grown
in the presence of diﬀerent BC concentrations (0.1, 0.5 or 1 mg/ml),
was evaluated by alkaline single cell gel assay (also known as comet
assay). Cells were incubated with BC suspensions for 48 h. Hydrogen
peroxide (100 mM) and water were used as positive and negative
controls, respectively. Damage to DNA was evaluated by image analysis
using the “Comet Assay IV version 4.2” image analysis system. Cells
grown on a BC membrane were also tested as a control. The results
showed that the DNA damages in the presence of BC ﬁbres are similar
to the negative control for each BC concentration. Around 95% of cells
showed none or insigniﬁcant DNA damage (comet class 0 and 1). Re-
garding the comet parameters obtained from image analyses, (tail
length, tail migration, percent tail DNA and tail moment), BC ﬁbres did
not induce DNA damages under the concentrations tested, as compared
to the negative and positive control. The results from visual scoring and
image analysis overall showed that, under the range of tested condi-
tions, BC was not genotoxic.
5.2. Salmonella/microsome mutagenicity assay (“Ames test”)
Schmitt et al. [28] studied the potential of BC in Cellulon to induce
gene mutations in a bacterial reverse mutation test with Salmonella
typhimurium strains TA 89, TA 100, TA 1535, TA 1537, and TA 1538 in
the absence and presence of a metabolic activation system (Table 3).
Cellulon, a mixture of BC:sucrose (1:1), was suspended in deionized
water and tested in a standard incorporation assay at 0, 66.7, 100, 333,
667, 1000, and 2500 μg/plate in each tested strain, with and without
metabolic activation. The maximum dose tested was limited by the
viscosity of BC. The results indicate that BC did not cause an increase in
the number of histidine revertants (mutations) per plate in any bacterial
strain, either in the presence or absence of S9 microsomal enzymes.
Moreira et al. [31] studied the mutagenic potential of BC nanoﬁbers
using the bacterial reverse mutation assay, using four strains Salmonella
tryphimurium (TA97a, TA98, TA100 and TA102) (Table 3). The test was
conducted in the presence or absence of a S9 mixture, using 0.1, 0.5 or
1.0 mg/ml of a bacterial cellulose suspension. The mutagenicity of BC
was evaluated according to the following parameters: the maximum
number of revertants in the presence of BC should be 2-fold or more
relative to the negative control; a dose-dependent increase in the
number of revertants should be observed. The results obtained, in the
presence of BC without S9 mixture, correspond to the spontaneous re-
version for each strain and are similar to those obtained to negative
control. In the presence of S9 mixture, an increase of revertant colonies
per plate, for the TA98 and TA100 strains, was detected as compared
with control; however, the increases were in each case< 2-fold and did
not appear to be dose-related. It was concluded that, under the condi-
tions tested, BC does not present a mutagenic behaviour [31].
Hagiwara et al. [30] evaluated the mutagenic potential of nata de
coco (BC) in mutant strains of S. typhimurium (TA97, TA98, TA100,
TA102), according to the norm GB 15193-2003 (Table 3). For this, SPF-
grade Sprague-Dawley (SD) rats’ liver S9 mixture was used as the
exogenous metabolic activation system. Five control groups (at 8, 40,
200, 1000 and 5000 μg CB/dish) were set up. The criteria for a positive
response were a≥ two-fold increase in the average plate count com-
pared with the solvent control for at least one concentration level and a
dose response over the range of tested concentrations in at least one
strain with or without S9. Results showed that the numbers of colonies
of each group at any BC dose, with or without S9 did, did not exceed
twice of those of spontaneous reverse mutation group. Reversion mu-
tation colonies did not grow with increasing dosages of BC, when
compared to the solvent plates, indicating that no dose-response re-
lationship was reﬂected. BC did not show any mutagenic activity under
the experimental conditions.
5.3. Cytogenetic assay measuring chromosomal aberration frequencies
Schmitt et al. [28] also performed cytogenetic assays with BC from
Cellulon (Table 3). For this, CHO cells were grown in a McCoy's 5a
culture medium. The assays were conducted with and without meta-
bolic activation. Target concentrations of 0.333 μg/ml to 10,000 μg/ml
Cellulon in McCoy's Sa culture medium, in a half-log series were tested
in range-ﬁnding assays. Cytotoxicity and cell cycle kinetics were eval-
uated, and the results were used to determine the dose levels in the
chromosomal aberrations assay. Results from this studied showed that
no signiﬁcant increase in cells with chromosomal aberrations was ob-
served at the Cellulon’s concentrations analysed. The BC in Cellulon
was considered negative for inducing chromosomal aberrations in CHO
cells under both non-activation and metabolic activation conditions.
5.4. Unscheduled DNA synthesis (UDS) assay
Unscheduled DNA Synthesis assay was performed by Schmitt et al.
(1991) with BC from Cellulon, using rat primary hepatocytes. The UDS
assay was initiated by replacing the media in the culture dishes with
2,5 mL WMEI containing about 10 μCi/ml 3H-thymidine (50 Ci/mmol)
and Cellulon at concentrations of 501, 1000, 2000, 3010, 4010, and
5010 μg/ml in WMEI culture medium). BC from Cellulon was shown
not to induce signiﬁcant changes in the nuclear labelling of rat primary
hepatocytes within the range of tested concentrations. None of the
criteria used to indicate UDS were approached by any of the analysed
treatments and no dose-related response was observed. However, the
assay system was demonstrated to be highly responsive to the positive
control, 2-acetylanunoﬂuorene which provided conclusive evidence of
the validity of the assay and the lack of UDS induction by BC from
Cellulon. In summary, BC was evaluated as inactive in the in vitro Rat
Primary Hepatocyte UDS Assay.
5.5. CHO/HGPRT forward mutation assay
Schmitt et al. [28] performed a Chinese hamster ovary cell/hy-
poxanthine-guanine phosphoribosyl-transferase Forward Mutation
Assay for the detection of mutagens in CHO-KI-BH4 cells (Table 3). BC
from Cellulon was not cytotoxic in either mutation assay (with or
without S9 metabolic activation) within the range of tested con-
centrations. The mutant frequencies of treated cultures varied randomly
with Cellulon dose, within the range acceptable for background mutant
frequencies which is less than 15 × 10−6. Of the 14 cultures treated
with Cellulon, only one culture, in the activation mutation assay, had a
mutant frequency that was statistically elevated over the mutant fre-
quencies of the concurrent vehicle control cultures. This observation is
consistent with normal variation in background mutant frequency in
independent cultures. Therefore, BC was considered negative for in-
ducing forward mutations at the HGPRT locus in CHO cells under both
nonactivation and S9 metabolic activation conditions.
5.6. Limulus amebocyte iysate (LAL) assay
Schmitt et al. [28] assayed the pyrogenicity of BC in Cellulon by
using the Limulus amebocyte Iysate (LAL) assay (Table 3). As negative
F. Dourado et al. Toxicology Reports 4 (2017) 543–553
548
Ta
bl
e
3
Su
m
m
ar
y
of
th
e
ge
no
to
xi
ci
ty
&
re
pr
od
uc
ti
ve
to
xi
co
lo
gy
st
ud
ie
s
w
it
h
ba
ct
er
ia
l
ce
llu
lo
se
.
Ty
pe
of
st
ud
y
C
el
l
lin
e/
an
im
al
m
od
el
D
os
ag
es
M
ai
n
re
su
lt
s
R
ef
.
In
vi
tr
o
C
om
et
as
sa
y
C
hi
ne
se
ha
m
st
er
ov
ar
y
(C
H
O
)
ce
lls
A
ss
ay
:0
.1
,0
.5
or
1
m
g
BC
/m
l
D
N
A
da
m
ag
es
in
th
e
pr
es
en
ce
of
BC
ﬁ
br
es
ar
e
si
m
ila
r
to
th
e
ne
ga
ti
ve
co
nt
ro
l
fo
r
ea
ch
BC
co
nc
en
tr
at
io
n;
M
or
ei
ra
et
al
.
[3
1]
Po
si
ti
ve
co
nt
ro
l:
hy
dr
og
en
pe
ro
xi
de
(1
00
m
M
)
A
ro
un
d
95
%
of
ce
lls
sh
ow
ed
no
ne
or
in
si
gn
iﬁ
ca
nt
D
N
A
da
m
ag
e
(c
om
et
cl
as
s
0
an
d
1)
N
eg
at
iv
e
co
nt
ro
l:
w
at
er
A
m
es
te
st
Sa
lm
on
el
la
ty
ph
im
ur
iu
m
(T
A
89
,T
A
10
0,
TA
15
35
,T
A
15
37
,T
A
15
38
)
w
it
h
an
d
w
it
ho
ut
m
et
ab
ol
ic
ac
ti
va
ti
on
A
ss
ay
:0
,6
6.
7,
10
0,
33
3,
66
7,
10
00
,
an
d
25
00
μg
/p
la
te
BC
di
d
no
t
ca
us
e
an
in
cr
ea
se
in
th
e
nu
m
be
r
of
hi
st
id
in
e
re
ve
rt
an
ts
(m
ut
at
io
ns
)
pe
r
pl
at
e
in
an
y
ba
ct
er
ia
ls
tr
ai
n,
ei
th
er
in
th
e
pr
es
en
ce
or
ab
se
nc
e
of
S9
m
ic
ro
so
m
al
en
zy
m
es
Sc
hm
it
t
et
al
.
[2
8]
Po
si
ti
ve
co
nt
ro
ls
us
ed
w
it
ho
ut
m
et
ab
ol
ic
ac
ti
va
ti
on
:
–
2-
ni
tr
oﬂ
uo
re
ne
(T
A
98
,T
A
15
38
)
–
so
di
um
az
id
e
(T
A
10
0,
TA
15
35
)
–
IC
R
-1
91
w
it
h
TA
15
37
–
Po
si
ti
ve
co
nt
ro
ls
w
it
h
m
et
ab
ol
ic
ac
ti
va
ti
on
:
–
2-
am
in
oa
nt
hr
ac
en
e
w
as
us
ed
w
it
h
al
l
st
ra
in
s
Sa
lm
on
el
la
tr
yp
hi
m
ur
iu
m
(T
A
97
a,
TA
98
,T
A
10
0
an
d
TA
10
2)
A
ss
ay
,w
it
h
an
d
w
it
ho
ut
S9
m
ix
tu
re
:0
.1
,0
.5
or
1.
0
m
g
BC
/m
l
Th
e
re
su
lt
s
ob
ta
in
ed
,i
n
th
e
pr
es
en
ce
of
BC
w
it
ho
ut
S9
m
ix
tu
re
,c
or
re
sp
on
d
to
sp
on
ta
ne
ou
s
re
ve
rs
io
n
fo
r
ea
ch
st
ra
in
an
d
ar
e
si
m
ila
r
to
th
os
e
ob
ta
in
ed
to
ne
ga
ti
ve
co
nt
ro
l;
M
or
ei
ra
et
al
.
[3
1]
N
eg
at
iv
e
co
nt
ro
l:
di
st
ill
ed
w
at
er
In
th
e
pr
es
en
ce
of
S9
m
ix
tu
re
,a
n
in
cr
ea
se
of
re
ve
rt
an
t
co
lo
ni
es
pe
r
pl
at
e,
fo
r
th
e
TA
98
an
d
TA
10
0
st
ra
in
s,
w
as
de
te
ct
ed
as
co
m
pa
re
d
w
it
h
co
nt
ro
l;
ho
w
ev
er
,t
he
in
cr
ea
se
s
w
er
e
in
ea
ch
ca
se
<
2-
fo
ld
an
d
di
d
no
t
ap
pe
ar
to
be
do
se
-r
el
at
ed
Po
si
ti
ve
co
nt
ro
ls
:
–
0.
1
μg
/p
la
te
4-
ni
tr
oq
ui
no
lin
e
1-
ox
id
e
(T
A
97
a,
TA
98
)
–
5.
0
μg
/p
la
te
so
di
um
az
id
e
(T
A
10
0)
–
0.
5
μg
/p
la
te
m
yt
om
ic
yn
C
(T
A
10
2)
S.
ty
ph
im
ur
iu
m
(T
A
97
,T
A
98
,T
A
10
0,
TA
10
2)
A
ss
ay
:8
,4
0,
20
0,
10
00
an
d
50
00
μg
C
B/
di
sh
Th
e
nu
m
be
rs
of
co
lo
ni
es
of
ea
ch
gr
ou
p
at
an
y
BC
do
se
,w
it
h
or
w
it
ho
ut
S9
di
d,
di
d
no
t
ex
ce
ed
tw
ic
e
of
th
os
e
of
sp
on
ta
ne
ou
s
re
ve
rs
e
m
ut
at
io
n
gr
ou
p;
H
ag
iw
ar
a
et
al
.
[3
0]
Po
si
ti
ve
co
nt
ro
ls
w
it
ho
ut
S9
:9
-ﬂ
uo
re
no
ne
,s
od
iu
m
az
id
e,
m
it
om
yc
in
C
;
R
ev
er
si
on
m
ut
at
io
n
co
lo
ni
es
di
d
no
t
gr
ow
w
it
h
in
cr
ea
si
ng
do
sa
ge
s
of
BC
,
w
he
n
co
m
pa
re
d
to
th
e
so
lv
en
t
pl
at
es
,i
nd
ic
at
in
g
th
at
no
do
se
-r
es
po
ns
e
re
la
ti
on
sh
ip
w
as
re
ﬂ
ec
te
d.
Po
si
ti
ve
co
nt
ro
ls
w
it
h
S9
:1
,8
-d
ih
yd
ro
xy
an
th
ra
qu
in
on
e,
2-
am
in
o
ﬂ
uo
ri
ne
C
yt
og
en
et
ic
A
ss
ay
C
H
O
ce
lls
A
ss
ay
:0
.3
33
μg
/m
l
to
10
,0
00
μg
/m
l
C
el
lu
lo
n
in
M
cC
oy
's
Sa
cu
lt
ur
e
m
ed
iu
m
N
o
si
gn
iﬁ
ca
nt
in
cr
ea
se
in
ce
lls
w
it
h
ch
ro
m
os
om
al
ab
er
ra
ti
on
s
w
as
ob
se
rv
ed
at
th
e
co
nc
en
tr
at
io
ns
an
al
ys
ed
;
[2
8]
Po
si
ti
ve
co
nt
ro
ls
:m
it
om
yc
in
C
,n
on
ac
ti
va
ti
on
se
ri
es
;
cy
cl
op
ho
sp
ha
m
id
e,
m
et
ab
ol
ic
ac
ti
va
ti
on
se
ri
es
BC
w
as
co
ns
id
er
ed
ne
ga
ti
ve
fo
r
in
du
ci
ng
ch
ro
m
os
om
al
ab
er
ra
ti
on
s
in
C
H
O
ce
lls
un
de
r
bo
th
no
n-
ac
ti
va
ti
on
an
d
m
et
ab
ol
ic
ac
ti
va
ti
on
co
nd
it
io
ns
U
D
Sa
A
ss
ay
R
at
pr
im
ar
y
he
pa
to
cy
te
s
A
ss
ay
:r
ep
la
ce
m
en
t
of
th
e
cu
lt
ur
e
m
ed
ia
w
it
h
–
2,
5
m
L
W
M
EI
w
it
h
10
μC
i/
m
l
3H
-t
hy
m
id
in
e
(5
0
C
i/
m
m
ol
),
BC
(5
01
,1
00
0,
20
00
,3
01
0,
40
10
,a
nd
50
10
μg
/m
l)
BC
di
d
no
t
to
in
du
ce
si
gn
iﬁ
ca
nt
ch
an
ge
s
in
th
e
nu
cl
ea
r
la
be
lli
ng
of
ra
t
pr
im
ar
y
he
pa
to
cy
te
s
w
it
hi
n
th
e
ra
ng
e
of
te
st
ed
co
nc
en
tr
at
io
ns
;
Po
si
ti
ve
co
nt
ro
ls
:(
2-
ac
et
yl
am
in
oﬂ
uo
re
ne
)
N
on
e
of
th
e
cr
it
er
ia
us
ed
to
in
di
ca
te
U
D
S
w
er
e
ap
pr
oa
ch
ed
by
an
y
of
th
e
an
al
ys
ed
tr
ea
tm
en
ts
an
d
no
do
se
-r
el
at
ed
re
sp
on
se
w
as
ob
se
rv
ed
N
eg
at
iv
e
co
nt
ro
l:
–
W
M
EI
w
it
h
10
pC
i/
m
l
3H
-T
dR
,
–
W
M
EI
w
it
h
su
cr
os
e
C
H
O
/H
G
PR
Tb
Fo
rw
ar
d
M
ut
at
io
n
A
ss
ay
C
H
O
-K
I-
BH
4
ce
lls
A
ss
ay
w
it
h
an
d
w
it
ho
ut
S9
m
et
ab
ol
ic
ac
ti
va
ti
on
:
BC
at
0.
09
8-
5.
0
m
g/
m
l,
in
F1
2
cu
lt
ur
e
m
ed
iu
m
BC
w
as
co
ns
id
er
ed
ne
ga
ti
ve
fo
r
in
du
ci
ng
fo
rw
ar
d
m
ut
at
io
ns
at
th
e
H
G
PR
T
lo
cu
s
in
C
H
O
ce
lls
un
de
r
bo
th
no
na
ct
iv
at
io
n
an
d
S9
m
et
ab
ol
ic
ac
ti
va
ti
on
co
nd
it
io
ns
N
eg
at
iv
e
co
nt
ro
l:
Su
cr
os
e
Po
si
ti
ve
co
nt
ro
l:
(n
on
ac
ti
va
ti
on
as
sa
y,
5-
br
om
o-
2′
de
ox
yu
ri
di
ne
(B
rd
U
)
M
et
ab
ol
ic
ac
ti
va
ti
on
:
3-
m
et
hy
lc
ho
la
nt
hr
en
e
(c
on
tin
ue
d
on
ne
xt
pa
ge
)
F. Dourado et al. Toxicology Reports 4 (2017) 543–553
549
Ta
bl
e
3
(c
on
tin
ue
d)
Ty
pe
of
st
ud
y
C
el
l
lin
e/
an
im
al
m
od
el
D
os
ag
es
M
ai
n
re
su
lt
s
R
ef
.
LA
Lc
as
sa
y
A
ss
ay
:B
C
(0
.5
%
C
el
lu
lo
n
ﬁ
br
e,
99
.5
%
w
at
er
)
BC
w
as
ne
ga
ti
ve
fo
r
th
e
pr
es
en
ce
of
gr
am
-n
eg
at
iv
e
ba
ct
er
ia
l
en
do
to
xi
n
(<
0,
25
EU
/m
l)
N
eg
at
iv
e:
st
er
ile
w
at
er
an
d
en
do
to
xi
n
M
ou
se
sp
er
m
ab
no
rm
al
it
y
te
st
K
un
m
in
g
m
al
e
m
ic
e
A
ss
ay
:B
C
m
ea
ls
w
it
h
1.
3,
2.
5,
5.
0
g/
K
g
bw
,t
hr
ou
gh
or
al
ga
va
ge
;
N
o
si
gn
iﬁ
ca
nt
di
ﬀ
er
en
ce
s
in
th
e
ra
te
of
sp
er
m
ab
no
rm
al
it
y
be
tw
ee
n
ea
ch
BC
do
sa
ge
gr
ou
p
an
d
th
e
so
lv
en
t
co
nt
ro
l
gr
ou
p
(C
M
C
);
Li
-m
in
g
et
al
.
[2
9]
N
eg
at
iv
e
co
nt
ro
l:
1%
C
M
C
Th
er
e
w
as
a
si
gn
iﬁ
ca
nt
di
ﬀ
er
en
ce
be
tw
ee
n
th
e
po
si
ti
ve
co
nt
ro
l
gr
ou
p
(c
yc
lo
ph
os
ph
am
id
e)
an
d
th
e
so
lv
en
t
co
nt
ro
l
gr
ou
p
Po
si
ti
ve
co
nt
ro
l:
cy
cl
op
ho
sp
ha
m
id
e,
(4
0
m
g/
kg
bw
)
Te
ra
to
ge
ni
ci
ty
te
st
Fe
rt
ili
ze
d
SD
ra
ts
A
ss
ay
:d
ur
in
g
ge
st
at
io
n
(7
–1
6
da
ys
),
do
sa
ge
gr
ou
ps
re
ce
iv
ed
or
al
ga
va
ge
of
1.
0,
2.
0,
4.
0
g
BC
/k
g;
N
o
de
at
hs
an
d
no
gr
os
s
an
at
om
ic
al
ab
no
rm
al
it
ie
s
w
er
e
ob
se
rv
ed
to
an
y
pr
eg
na
nt
ra
t
in
al
l
gr
ou
ps
;
C
on
tr
ol
gr
ou
p:
10
.0
m
L/
kg
bw
of
1%
C
M
C
N
o
ab
no
rm
al
it
ie
s
in
th
e
an
at
om
y
of
th
e
ra
ts
in
ea
ch
do
se
gr
ou
p;
N
o
si
gn
iﬁ
ca
nt
di
ﬀ
er
en
ce
s
in
th
e:
–
w
ei
gh
t
an
d
w
ei
gh
t
ga
in
of
pr
eg
na
nt
ra
ts
,
–
pl
ac
en
ta
l
w
ei
gh
t,
–
in
ci
de
nc
e
of
fo
et
al
an
d
st
ill
bi
rt
h
in
pr
eg
na
nt
ra
ts
,
–
fo
et
al
bo
dy
le
ng
th
an
d
ta
il
le
ng
th
,
–
ab
so
rp
ti
on
ra
te
(0
–5
.8
%
),
ra
te
of
st
ill
bi
rt
h
(0
%
),
ra
te
of
m
al
fo
rm
at
io
n
(0
%
),
ra
te
of
vi
sc
er
al
de
fo
rm
it
y
(0
%
),
–
lit
te
r
si
ze
an
d
sk
el
et
al
de
fo
rm
it
ie
s,
be
tw
ee
n
ea
ch
do
se
gr
ou
p
an
d
th
e
co
nt
ro
l
gr
ou
p
In
vi
vo
M
ou
se
bo
ne
m
ar
ro
w
m
ic
ro
nu
cl
eu
s
as
sa
y
K
un
m
in
g
m
ic
e
A
ss
ay
:o
ra
l
ga
va
ge
of
1.
3,
2.
5,
5.
0
g
BC
/K
g
bw
N
o
si
gn
iﬁ
ca
nt
di
ﬀ
er
en
ce
s
in
th
e
in
ci
de
nc
e
of
m
ic
ro
nu
cl
eu
s
in
th
e
bo
ne
m
ar
ro
w
of
fe
m
al
e
an
d
m
al
e
m
ic
e
in
ea
ch
do
se
gr
ou
p,
as
co
m
pa
re
d
to
th
e
so
lv
en
t
co
nt
ro
l
gr
ou
p
(C
M
C
);
H
ag
iw
ar
a
et
al
.
[3
0]
N
eg
at
iv
e
co
nt
ro
l:
1%
C
M
C
Th
e
m
ic
ro
nu
cl
eu
s
ra
te
in
th
e
po
si
ti
ve
co
nt
ro
lg
ro
up
(c
yc
lo
ph
os
ph
am
id
e)
w
as
si
gn
iﬁ
ca
nt
ly
hi
gh
er
th
an
th
at
of
th
e
C
M
C
gr
ou
p
Po
si
ti
ve
co
nt
ro
l:
cy
cl
op
ho
sp
ha
m
id
e,
at
40
m
g/
kg
bw
a
U
ns
ch
ed
ul
ed
D
N
A
Sy
nt
he
si
s.
b
C
hi
ne
se
ha
m
st
er
ov
ar
y
ce
ll/
hy
po
xa
nt
hi
ne
-g
ua
ni
ne
ph
os
ph
or
ib
os
yl
-t
ra
ns
fe
ra
se
.
c
Li
m
ul
us
am
eb
oc
yt
e
Iy
sa
te
.
F. Dourado et al. Toxicology Reports 4 (2017) 543–553
550
control, sterile water and endotoxin dilutions, that labelled sensitivity
of the lysate, were used. BC was negative for the presence of gram-
negative bacterial endotoxin (< 0,25 EU/ml).
In this paper, no details were provided on the puriﬁcation procedure
for Cellulon. Lipopolysaccharide (LPS) is a characteristic pathogen-as-
sociated molecular pattern (PAMP) present in the outer membrane of
all Gram-negative bacteria. LPS is widely known for triggering an ex-
tremely violent and uncontrolled immune response. Once LPS is re-
cognized in the blood stream, it causes severe cytokine-mediated da-
mage, ultimately leading to death [32]. Along with native bacteria
removal, remnants from the culture media, BC puriﬁcation methods
must ensure the absence of LPS in the ﬁnal product, if it is to be used in
food and biomedical applications. Usually this is achieved through the
use of alkali solutions, sodium dodecylsulphate, high temperature and
sterilization [33–35].
5.7. Mouse sperm abnormality test
Li-ming et al. [29] performed the mouse sperm abnormality test, to
detect reproductive toxicity, on 25 Kunming male mice, divided into 5
groups (Table 3). Dose design was as follows: BC concentrations were
1.3, 2.5, 5.0 g/Kg bw, through oral gavage; the negative control group
was fed with 1% CMC and the positive control group, cyclopho-
sphamide, at 40 mg/kg bw. Results from this test showed that, after
35 days, there were no signiﬁcant diﬀerences in the rate of sperm ab-
normality between each BC dosage group and the solvent control group
(CMC), but there was a signiﬁcant diﬀerence between the positive
control group (cyclophosphamide) and the solvent control group. These
results suggest that BC did not induce any reproductive toxicity, under
the conditions tested.
5.8. Bone marrow cell micronucleus test
Li-ming et al. [29] performed the mouse bone marrow micronucleus
assay (Table 3). For this, Kunming mice were divided in groups 3
groups of 10 each (in each group, half male and half female). Three BC
concentrations were tested: 1.3, 2.5, 5.0 g/Kg bw, through oral gavage.
The negative control group was fed with 1% CMC, whereas cyclopho-
sphamide, at 40 mg/kg bw, was fed to positive control group. Mice
were fed twice, with a 24 h interval between meals, at a dosage of
20 mL/kg bw. Six hours after the last administration, the animals were
euthanized. Results from the bone marrow micronucleus test showed
that there were no signiﬁcant diﬀerences in the incidence of micro-
nucleus in the bone marrow of female and male mice in each dose
group, as compared to the solvent control group (CMC), but the mi-
cronucleus rate in the positive control group (cyclophosphamide) was
signiﬁcantly higher than that of the CMC group. These results indicated
that the dry powder of BC was not mutagenic for mice.
5.9. Teratogenicity test
Li-ming et al. [29] performed the teratogenicity tests on fertilized
SD rats, according to the norm GB 15193-2003 (Table 3). Rats were
randomly divided into four groups of 12. In the gestation of 7–16 days,
the dosage groups received oral gavage of 10.0 mL/kg bw at 1.0, 2.0,
4.0 g BC/kg, while the control group, received 10.0 mL/kg bw of 1%
CMC. During the gestation, no deaths and no gross anatomical ab-
normalities were observed to any pregnant rat in all groups. There were
no abnormalities in the anatomy of the rats in each dose group. There
were no signiﬁcant diﬀerences in the weight of pregnant rats, placental
weight, weight gain, on the incidence of foetal and stillbirth in pregnant
rats compared with solvent control group. There were also no sig-
niﬁcant diﬀerences in foetal body length and tail length, between each
dose group and control group. There were no signiﬁcant diﬀerences in
the absorption rate (0–5.8%), the rate of stillbirth (0%), the rate of
malformation (0%), the rate of visceral deformity (0%), litter size and
skeletal deformities, between each dose group and the control group.
The results obtained indicated that BC (nata de coco) showed no em-
bryotoxicity and teratogenicity.
A summary of the above-mentioned studies is present in Table 3.
5.10. Lung, eye and dermal toxicity
Schmitt et al. [28] evaluated the primary eye and dermal irritation
of Cellulon, on adult female New Zealand White rabbits. Fifty mg of the
Cellulon powder was placed in the conjunctival sac of the left eye of
each rabbit. The upper and lower lids were gently held together for 1 s
following instillation, to prevent the loss of material and then released.
The right eye of the rabbit remained untreated and served as the con-
trol. All rabbits survived to study termination. Minor conjunctival ir-
ritation was observed in several animals after 1 h post-treatment. The
observable irritation (in 4 out of 6 animals) was characterized as Grade
1 for redness and Grade 1 for chemosis (2 out of 6 animals). The redness
subsided in all but one animal at 24 h post-dose observation and in all
animals after 72-h observation. Chemosis persisted in one animal at
24 h post-dose observation, but was absent at 48 h evaluation. No ir-
ritation was noted in the cornea or iris. Due to the dry, granular form of
Cellulon ﬁbre, the resultant irritation was considered to be of me-
chanical nature.
For the primary dermal irritation study, Cellulon ﬁbre (0.5 g in
0.5 mL of tap water) was applied to an area (approximately 2 × 2 in-
ches) of the dorsal surface of the intact, shaved skin of rabbits and held
in place with a taped gauze patch and non-absorbent binding, for 4 h.
The patch was then removed, and at certain intervals, the degree of
erythema and edema was evaluated according to the Draize method. As
above, all rabbits survived to study termination. No erythema, edema,
or other dermal eﬀects were noted throughout the study. Under the
conditions tested, Cellulon ﬁbre, did not to induce a dermal irritation in
New Zealand white rabbits.
No other studies on the dermal sensitization and dermal toxicity of
BC were found in the literature. However, there have been several
publications on the successful use of BC in humans, has a wound
dressing. A commercial product from BC, called Bioﬁll®, has been used
for several skin injury treatments such as basal cell carcinoma/skin
graft, severe body burns, facial peeling, sutures, dermabrasions, skin
lesions, chronic ulcers, and both donor and receptor sites in skin grafts
[36]. The clinical applications of BC as a wound dressing in humans
have been reviewed [37–41]. BC has also been used in cosmetic ap-
plications, mostly as a facial masks (BC thin and hydrated membrane),
facial scrub (BC dispersion) and proposed also to be used has a trans-
dermal drug delivery agent (BC thin and hydrated membrane)
[42,41,43–45]. From the above, it is unlikely that BC will induce any
dermal irritation on humans.
No studies were found addressing the pulmonary toxicity of BC, but
there are a few studies with plant celluloses. As pilot scale productions
of plant nanocelluloses (nanoﬁbrillar, nanocrystals) are emerging, and
due to the higher aspect ratio of these nano-scalar ﬁbres, occupational
exposure studies to have also been receiving increasingly more atten-
tion. Still, studies on the eﬀects of exposure of “nano” celluloses by
inhalation routes are still scarce [46–58].
6. Inﬂammatory response
BC has long been explored for use as a biomaterial, such as artiﬁcial
skin/wound dressing, artiﬁcial blood vessels, artiﬁcial cornea, heart
valve prosthesis, artiﬁcial urethra, artiﬁcial bone, artiﬁcial cartilage,
artiﬁcial porcine knee menisci, to name a few examples. BC has also
been explored for the delivery of drugs, hormones and proteins. The
biocompatibility and hemocompatibilty of BC has been demonstrated in
vitro and in vivo. In general, BC can be considered to be broadly bio-
compatible, invoking only moderate (if any) foreign body response in
vivo [42,59,38,60–63]. After 12 weeks following subcutaneous BC
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implantation in female Wistar rats, Helenius et al. [64] found that no
ﬁbrotic capsule or giant cells were detectable by microscopy, indicating
that no foreign body reaction occurred. Also, macroscopically, no red-
ness, swelling, or exudate developed around the implantation sites was
observed. Klemm et al. [65] demonstrated the in vivo (white rat
(Han:WIST)) biocompatibility of BC implants, using BASYC® (Bacterial
Synthesized Cellulose) tubes, for use as artiﬁcial blood vessels and on
micronerve surgery. Schumann et al. [66] and Wippermann et al. [67]
also studied in vivo the potential of BC, for use in tissue-engineered
blood vessels, using pigs as animal models. Andrade et al. [68] in-
vestigated the biocompatibility of BC and peptide (Arg-Gly-Asp)-mod-
iﬁed BC membranes subcutaneously implanted in white merino sheep,
for up to 32 weeks. Compared with negative control samples (expanded
polytetraﬂuoroethylene (ePTFE)), peptide-modiﬁed BC membranes
were only mildly irritating to the tissue, with no signiﬁcant diﬀerences
in the inﬂammation degree. In another study, by Pertile et al. [69] the
in vivo biocompatibility of BC was evaluated, through histological
analysis of long-term (up to 12 months) subcutaneous implants in male
BALB/c mice. BC implants caused a mild and benign inﬂammatory
reaction that decreased with time and did not elicit a foreign body re-
action. Moreover, no diﬀerences were observed between the controls
(without implants) and BC implanted animals, in thymocyte popula-
tions and in B lymphocyte precursors and myeloid cells in the bone
marrow. Svensson et al. [70] studied in vitro, the potential of BC as a
scaﬀold for cartilage repair. In this study, BC did not induce signiﬁcant
activation of pro-inﬂammatory cytokine production during in vitro
macrophage screening. Xu et al. [71] explored the use of BC as an ar-
tiﬁcial dura mater and examined the histocompatibility and in-
ﬂammatory eﬀects of this BC implant in New Zealand rabbits. There
were seldom inﬂammatory cells surrounding the BC membrane, during
early postoperative period. The expression of inﬂammatory cytokines
IL-1β, IL-6 and TNF-α as well as iNOS and COX-2 were lower in the BC
group compared to the control group (with NormalGEN® membrane
(Biological Dural Repairing Patch)) for up to 21 days after implanta-
tion. BC was observed to allow the repairing of dural defects in rabbit
and had a decreased inﬂammatory response compared to traditional
materials. Panerari et al. [72] studied in vivo, using rabbits as animal
models, the use of a commercial product from BC (Bionext®) as a
dressing to prevent scarring tissue formation, following tracheal ste-
nosis surgery. Bionext dressings were observed not to induce acute in-
ﬂammatory response, up to 180 days following scariﬁcation. Andrade
et al. [73] studied the in vitro hemocompatibility of BC and BC-based
biomaterials. It was reported that native BC and peptide (Arg-Gly-Asp)-
modiﬁed BC membranes both preserved original conformational
structures and exhibited a favourable interaction (non-activation) with
platelets, which were indicative that BC and modiﬁed BC could be
considered hemocompatible materials. As a matter of fact, several
companies have medical devices based on BC in the market (e.g. dura
mater allografts from DePuy Synthes from Johnson & Johnson, wound
dressings from Bowil Biotech), meaning that puriﬁed BC can meet the
strict regulatory requirements for this class of products.
7. Conclusion
In response to legislation, scientiﬁc developments, and public con-
cerns, toxicity-testing methods have been implemented, to generate
information on the potential hazards or risks posed to humans by the
use of several agents. Due to primary concerns on the toxicity, cancer
and reproductive development of human food substances, their place-
ment on the market is often dependant on regulatory approval. This has
become increasingly important, due to the growing interest in the use of
nano-sized biopolymers in the food sector, among them, nanocelluloses.
Bacterial cellulose (BC) is a biopolymer synthesized by
Komagataeibacter strains. The unique properties of this biopolymer have
allowed its exploitation in the development of numerous bio-based
products and applications. Several food applications of BC have been
proposed, due to its potential as a gelling, thickening, suspending and
stabilizing agent, along with its potential role as a source of dietary
ﬁbre. This manuscript addressed the safety of BC for human food ap-
plications. Information here reviewed on the toxicological data of BC, in
animals and in vitro, strongly suggest that BC is not genotoxic, carci-
nogenic, tumour promoter, pyrogenic or a developmental or re-
productive toxicant and thus it is not expected to pose any adverse side
eﬀects when used in human foods. In addition, the data available
supports the general conclusion that BC is non-toxic on ingestion, skin
contact or on inhalation, or elicit any other inﬂammatory or oxidative
stress responses at the cellular level.
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